Our mission - is to facilitate the transition of the Russian pharmaceutical market to develop into mature, be a guide on the course of development of the potential of all the pharmaceutical market participants, thereby improving the quality of life for the end user and society in general. Despite the relatively high susceptibility to Russia's external economic and financial risks, imbalances in the domestic policy and great social disparities, the pharmaceutical market in Russia has had a stable positive growth for the last few years.
The plenary meeting of the Vedomosti Publishing House "Legal Issues of the Pharmaceutical Industry" began with a discussion of a rather topical and ill topic "Pricing: Features and Innovations". The topic is relevant not only for the Russian pharmaceutical market, but for the global pharmaceutical market as a whole, the moderator of the session, Director General of the ARPF Viktor Dmitriev, said in his opening remarks.
According to the analytical company DSM Group, the volume of the commercial drug market in August 2017 amounted to 52.6 billion rubles (VAT included), which is 5.2% more than in July 2017. Relative to August 2016, sales increased by 9.7%.
According to the company DSM Group, for the first half of this year the sales of funds for care for patients increased by 8.4% compared to the same period in 2016 and reached 154 million packs. In terms of value, the growth of this market segment amounted to 8%. For the first half of 2017, $ 6.1 billion rubles in retail prices were sold for patient care.
The interdepartmental commission on the formation of lists of medicines under the Ministry of Health in 2017 carried out constructive work. At the same time, the level of quality of its activities is growing. About this, during the event dedicated to the 15th anniversary of the ARPF, said the chairman of the commission - the director of the Department of drug supply and regulation of medical supplies Elena Maksimkina.
The Commission of the Ministry of Health of the Russian Federation on the formation of lists does not fulfill "barrier functions" in the formation of a list of vital and essential medicines and does not facilitate the introduction of the most effective and economically justified medicines on the market for state financing. This opinion was expressed by Vitaly Omelyanovski, Director General of the Federal State Examination Center "Center for Expertise and Quality Control of Medical Aid" of the Ministry of Health of the Russian Federation.
• The representative of Merck noted the crucial role of cooperation between the pharmaceutical industry and the suppliers of technological solutions in order to comply with all GMP requirements already at the stage of development of production processes.
Elena Maksimkina, the head of the drug supply department of the ministry, informed that the commission of the Ministry of Health of the Russian Federation on the formation of lists of medicines approved the inclusion of 60 new international non-patented names (INNs), 8 new dosage forms in the list of vital and essential medicines (VNIV), while two preparations were excluded from the list.
At the end of this year, the order of appearance of new drugs on the shelves should change. The Ministry of Health prepared a bill simplifying the issue of medicines in the civil circulation. Now the document is being discussed publicly, it is planned to adopt it before the end of the year.